List of Vyondys 53 drug patents

Vyondys 53 is owned by Sarepta Theraps Inc.

Vyondys 53 contains Golodirsen.

Vyondys 53 has a total of 8 drug patents out of which 0 drug patents have expired.

Vyondys 53 was authorised for market use on 12 December, 2019.

Vyondys 53 is available in solution;intravenous dosage forms.

Vyondys 53 can be used as treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping.

Drug patent challenges can be filed against Vyondys 53 from 2023-12-13.

The generics of Vyondys 53 are possible to be released after 12 December, 2026.

VYONDYS 53's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47691 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 12, 2026
New Chemical Entity Exclusivity (NCE) Dec 12, 2024

Drugs and Companies using GOLODIRSEN ingredient

NCE-1 date: 2023-12-13

Market Authorisation Date: 12 December, 2019

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VYONDYS 53 family patents

53

United States

9

European Union

3

Spain

2

Hong Kong

2

Slovenia

2

Croatia

2

Denmark

2

Cyprus

2

Australia

2

Poland

1

Germany

1

Hungary

1

Portugal

1

Austria

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in